Loading...
01/11 03:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: a revenue decline, increased operating expenses, and a net loss, all of which are negative indicators. Additionally, the lack of a share repurchase program and competitive pressures in the market further dampen sentiment. Despite some positive aspects like the Fair Deal Agreement and potential international expansion, these are overshadowed by the financial and competitive challenges. The Q&A session did not alleviate these concerns, with management avoiding specific guidance. These factors suggest a negative stock price reaction in the short term.
Revenue $8.3 million, down from $10.7 million in Q1 2024, primarily due to lower unit sales to the largest customer.
Gross Profit $4.4 million, resulting in a gross margin of 52%, reflecting lower sales and higher costs associated with services provided.
Operating Expenses Increased significantly, with General and Administrative expenses rising to $2.2 million from $1.6 million a year ago due to professional fees and compensation.
Net Loss $2.6 million or a loss of $0.16 per share, compared to net income of $2.3 million or $0.14 per diluted share in the prior year quarter.
Adjusted EBITDA Negative $2.5 million for Q1 2025, compared with a positive $3 million a year ago, reflecting higher operating expenses and lower revenue.
Cash Position $19.1 million in cash, no debt.
Inventory $9.9 million, maintained to meet anticipated demand in upcoming quarters.
Transdermal Infusion System (TDI): Enhancements to the TDI are in progress, with a 510(k) application resubmitted in early March, expecting FDA determination by year-end.
Fair Deal Agreements: Initiated 11 fair deal agreements with six going live in Q1, expecting significant revenue contributions starting in the second half of 2025.
International Expansion: Attended the ESTRO show in Vienna and will exhibit at the Australian Academy of Dermatology Annual Meeting.
Installed Systems: Shipped 21 SRT systems, bringing total installed base to over 880 systems, on track to surpass 900 by Q2.
Revenue Performance: Q1 revenue was $8.3 million, down from $10.7 million in Q1 2024, but expected to increase in Q2 and the second half of the year.
Marketing Initiatives: Significant investments in sales and marketing, including participation in major industry events, to enhance brand visibility and customer engagement.
Profitability Outlook: Expect to return to profitability in each of the next three quarters and for the full year.
Revenue Decline: Revenue for Q1 2025 was $8.3 million, down from $10.7 million in Q1 2024, primarily due to lower unit sales to the largest customer.
Increased Operating Expenses: Operating expenses were significantly higher compared to the prior year, reflecting strategic growth initiatives, with general and administrative expenses rising due to professional fees and compensation.
Net Loss: Reported a net loss of $2.6 million for Q1 2025, compared to a net income of $2.3 million in the prior year quarter.
Market Competition: The company faces competitive pressures in the dermatology market, particularly with the adoption of their fair deal agreement initiative.
Regulatory Risks: The company is awaiting FDA review for their transdermal infusion system, with a six to nine month review cycle, which poses uncertainty regarding market launch.
Supply Chain Challenges: The company anticipates demand for SRT systems, which may strain supply chain capabilities if not managed effectively.
Economic Factors: The overall economic environment may impact customer spending and investment in new technologies, affecting revenue growth.
Sales and Marketing Initiatives: Invested in sales and marketing initiatives to enhance brand visibility and awareness of the fair deal agreement program.
Fair Deal Agreement Program: Secured multiple new fair deal agreements, with expectations of significant revenue contributions starting in the second half of 2025.
International Strategy: Progressing with international strategy, including participation in major industry events and exhibitions.
Product Innovation Pipeline: Advancements in the transdermal infusion system (TDI) with a 510(k) application resubmitted, expecting FDA determination by year-end.
Revenue Expectations: Expect Q2 revenue to be higher than Q1 and anticipate higher revenue in the second half of the year compared to the first half.
Profitability Outlook: Expect to return to profitability in each of the next three quarters and to be profitable for the full year.
Operating Expenses: General and administrative expenses expected to stabilize at approximately $1.8 million per quarter for the rest of the year.
R&D Expenses: Expect R&D expenses to be about $1.5 million per quarter for the remainder of the year.
Share Repurchase Program: None
The earnings call reveals declining financial metrics, including reduced units sold, gross profit, and increased net loss, indicating weakening financial health. Despite some positive elements, like international expansion and potential breakeven in Q4, the negative trends, including a significant drop in gross margin and increased operating expenses, dominate. The Q&A section did not alleviate concerns, as management's responses lacked clarity on critical timelines. Given these factors, the stock is likely to experience a negative reaction in the near term.
The earnings call revealed significant declines in gross profit, gross margin, and a shift from net income to net loss, indicating financial challenges. The Q&A highlighted uncertainties around CMS reimbursement, impacting sales and causing a large customer to pause purchases. Despite some international sales optimism, the lack of clear guidance on reimbursement and increased operating expenses suggest a negative short-term outlook. The overall sentiment leans negative due to financial performance issues and unresolved reimbursement concerns.
The earnings call summary reflects several concerns: declining revenue, increased operating expenses, and a net loss compared to the previous year. While management expects future profitability, lack of formal guidance and reliance on a few key customers pose risks. No shareholder return initiatives were announced, and competitive pressures remain. Despite some positive aspects like cash position and international expansion, the overall sentiment is negative, as financial metrics are weak, and uncertainties in market demand persist.
The earnings call reveals several concerns: a revenue decline, increased operating expenses, and a net loss, all of which are negative indicators. Additionally, the lack of a share repurchase program and competitive pressures in the market further dampen sentiment. Despite some positive aspects like the Fair Deal Agreement and potential international expansion, these are overshadowed by the financial and competitive challenges. The Q&A session did not alleviate these concerns, with management avoiding specific guidance. These factors suggest a negative stock price reaction in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
